Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(5 sites)
China
Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing
Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin
Tianjin medical university cancer institute & hospital, Tianjin
Hubei Cancer Hospital, Wuhan
The First Affiliated Hospital of Zhengzhou University, Zhengzhou